To investigate the association of body mass index (BMI) in early adulthood and endometrial cancer risk for carriers of a germline mutation in a DNA mismatch repair gene.
L ynch syndrome is caused by a germline mutation in one of the DNA mismatch repair genes MLH1, MSH2, MSH6, and PMS2. 1 Approximately one in 3,000 people carry a germline mutation in a mismatch repair gene 2 and are at substantially increased risk of colorectal, endometrial, ovarian, and other cancers. [3] [4] [5] Cumulative risk of endometrial cancer to age 70 years is estimated to be: 44% for MLH1 and MSH2 mutation carriers, 5 26% for MSH6 mutation carriers, 3 and 15% for PMS2 mutation carriers. 4 Physical characteristics or environmental exposures of the mutation carriers could also modify risk of developing endometrial cancer. 6 Although obesity is an established risk factor for endometrial cancer in the general population, [7] [8] [9] [10] [11] [12] the role of obesity in endometrial cancer risk is not well understood for mismatch repair gene mutation carriers. Body mass index (BMI) is a commonly used statistical measure of body mass adjusted for an individual's height (calculated as weight (kg)/[height (m)] 2 ). A BMI of 30 or greater is a commonly used definition of obesity. 13 To date, there have been three clinical studies investigating risk factors including BMI of endometrial cancer in mismatch repair gene mutation carriers but all of have been based on small numbers of Lynch syndrome families. 14, 15, 16 Several studies [17] [18] have observed a positive association between BMI in early adulthood and subsequent endometrial cancer risk for the general population. Determining the association of BMI in early adulthood on subsequent cancer risk would be important for mismatch repair gene mutation carriers who learn of their mutation status as young adults with the consequent opportunity to reduce their risk of disease. In this study, we investigated the association between BMI at age 18 -20 years and endometrial cancer risk for mismatch repair gene mutation carriers and, as a comparison, estimated the association for noncarriers.
PARTICIPANTS AND METHODS
Study participants for this analysis were recruited and genetically characterized by the Colon Cancer Family Registry. Study designs and recruitment methods can be found at http://epi.grants.cancer.gov/CFR/ and have been described in detail elsewhere. 19 Briefly, probands and their relatives were recruited between 1997 and 2007. Probands were either a recently diagnosed colorectal cancer case reported to a population complete cancer registry or an attendee to a family cancer clinic. For population-based ascertainment, probands were incident colorectal cancer cases recruited from cancer registries in the United States (Puget Sound, Washington; the state of Minnesota; Los Angeles, California; Arizona; Colorado; New Hampshire; North Carolina; and Hawaii), Australia (Victoria), and Canada (Ontario). Their first-degree relatives were recruited by all centers, and recruitment extended to more distant relatives by some centers. For clinic-based ascertainment, probands were selected from multiple-case colorectal or Lynch syndrome cancer families who attended family cancer clinics in the United States (Mayo Clinic, Rochester, Minnesota; and Cleveland, Ohio), Australia (Melbourne, Adelaide, Perth, Brisbane, Sydney), and New Zealand (Auckland). Their relatives were recruited according to prespecified rules of recruiting centers (for details, see Newcomb et al 19 ). Written informed consent was obtained from all participants, and the study protocol was approved by local institutional research ethics review boards.
At recruitment, baseline information on demographics, personal characteristics, personal and family history of cancer, cancer screening, and surgery including gynecologic surgery were obtained from all participants. Participants were followed up approximately 5 years after baseline to update demographic information, personal characteristics, and personal and family history of cancer, cancer screening, and surgery. Baseline and follow-up questionnaires are available at https://cfrisc.georgetown.edu/isc/dd.questionnaires. do. Reported cancer diagnoses and age at diagnosis were confirmed, where possible, using pathology reports, medical records, cancer registry reports, death certificates, or all of these. Blood samples and tumor tissue samples were collected for mutation testing. This study was based on all available baseline and follow-up data.
Self-reported weight at age 18 -20 years and current height were collected at standardized personal interviews (University of Southern California Consortium), telephone interviews (University of Southern California Consortium, Fred Hutchinson Cancer Research Center, and University of Melbourne), or from mailed questionnaires (University of Hawaii, Cancer Care Ontario, and Mayo Clinic).
Mutation testing for MLH1, MSH2, MSH6, and PMS2 was performed for all probands ascertained from family cancer clinics and for those probands from population-based ascertainment who had a colorectal tumor displaying evidence of impaired mismatch repair function as evidenced by either microsatellite instability or lack of mismatch repair protein expression by immunohistochemistry. Mutation testing was performed by Sanger sequencing or denaturing high pressure liquid chromatography followed by confirmatory DNA sequencing. Large insertion and deletion mutations were detected by multiplex ligation dependent probe amplification according to the manufacturer's instructions. 4, 19, 20 All participants who donated a blood sample, and who were relatives of probands with a pathogenic mutation, underwent predictive testing for the same mutation identified in the proband. All noncarriers were therefore relatives who tested negative for the mutation identified for the proband.
For this study, we have included female probands and their participating female relatives who were confirmed carriers and confirmed noncarriers of a mismatch repair gene mutation. We identified a total of 634 female carriers and 574 female noncarriers. Of these, 33 (5%) carriers and 41 (7%) noncarriers were excluded as a result of missing data for current height or weight at age 18 -20 years. The remaining 601 carriers (109 from population-based sources) and 533 noncarriers (57 from population-based sources) were included in the analyses. Excluded individuals did not differ in baseline characteristics from those who entered into the analyses (data not shown).
We were unable to analyze the role of current BMI in this study because it was not available 1-2 years before age at diagnosis or censored age for 392 women, which is 35% of the total study sample. These constituted 107 endometrial cancer cases (100 carriers and seven noncarriers) and 164 cases of other cancer (127 carriers and 37 noncarriers), 116 women with a prior hysterectomy (70 carriers and 46 noncarriers), and five women who did not report current weight at last contact.
A pathogenic mutation was defined as a variant that was predicted to result in a stop codon, a frameshift mutation, a large insertion or deletion, or a missense mutation previously reported in the scientific literature to be pathogenic. Height and weight were defined as self-reported current height and weight at age 20 years. Body mass index at age 20 years was calculated as weight in kilograms at age 20 years divided by height in meters squared.
Mismatch repair gene mutation carrier and noncarrier women were treated as a cohort from birth and Cox proportional hazard regressions were used to estimate associations between BMI and risk of endometrial cancer. The time at risk for each participant started at birth and ended at the age of diagnosis of endometrial cancer or any other cancer, hysterectomy, death, or last contact, whichever occurred first. The rationale for censoring at diagnosis of any cancer was that the resultant treatment and surveillance might alter risk of subsequent cancers, including endometrial cancer. Of the total 601 mutation carriers, observation time ended at age of diagnosis for 126 endometrial cancer cases and was censored at age of diagnosis of other cancer for 204 women, at age of hysterectomy for 81 women, at age of death for two women, and at age of last contact for 188 women. Of the total 533 noncarriers, time of observation ended at the age of diagnosis for eight endometrial cancer cases and was censored at the age of diagnosis of other cancer for 60 women, at age of hysterectomy for 57 women, at age of death for two women, and at age of last contact for 406 women.
Because a proportion of participants from this study were ascertained from multiple cancer-case families and because cases were tested preferentially for mismatch repair gene mutations, participant selection for testing mismatch repair gene mutation was not random with respect to the disease status. To obtain a synthetic cohort representative of mismatch repair gene mutation carriers and noncarriers, we adjusted for this nonrandom ascertainment by applying probability weights to both carriers and noncarriers based on the approach described by Antoniou et al, 21 which has been used for modifier studies of cancer risk for carriers of rare genetic mutations, eg, Brohet et al 22 and Andrieu et al. 23 This method removes bias when the external rates were correctly specified and reduces bias even when the sampling fractions were not completely accurate. 21 Age-specific incidence rates of endometrial cancer for carriers were calculated by multiplying the country-and age-specific population incidence by the hazard ratio of endometrial cancer for carriers of specific mismatch repair gene mutations. As a result of the rarity of mutations in the population, 2 agespecific incidence rates for noncarriers were assumed to equal those for the general population. Average age-specific population incidences in 1998 -2002 for each country (Australia, Canada, and the United States) were obtained from Cancer Incidence in Five Continents. 24 Using these age-specific incidence rates of endometrial cancer for carriers and noncarriers, we calculated statistical weights for endometrial canceraffected carriers, unaffected carriers, affected noncarriers, and unaffected noncarriers for each age stratum.
Hazard ratios and 95% confidence intervals (CIs) were estimated for associations between BMI and endometrial cancer risk. The proportional hazards assumption was tested by examining the relationship between the scaled Schoenfeld residuals and survival time. 25 Body mass index was fitted as a continuous variable as well as a categorical variable (less than 25 and 25 or greater). Body mass index as a continuous variable was considered to be the main exposure variable. To determine whether the association between BMI and the (log) hazard rate was nonlinear, we tested a range of nonlinear models using fractional polynomials. 26 We compared these models with the linear model using the Wald test.
To control for potential confounding factors potentially present at the age that BMI was reported for (ie, 18 -20 years old), we adjusted for 1) hormonal contraceptives use at age 20 (never, ever); 2) cigarette smoking at age 20 years (never, ever); 3) year of birth (before 1940, 1940 -1949, 1950 -1959, 1960 or after), and 4) age at menarche in years in both mutation carriers and noncarriers and further adjusted for carriers 5) the mismatch repair gene that was mutated. To compare the associations between BMI and endometrial cancer for mutation carriers with noncarriers, we tested for an interaction between mutation carrier status and BMI. To account for correlation of risk between family members, the Huber-White robust variance correction was applied by clustering on family membership. 27, 28 All statistical tests were two-sided and, PϽ.05 was considered statistical significance for testing a predetermined null hypothesis. All statistical analyses were performed using Stata 10.0.
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RESULTS
The study comprised 601 female carriers of a mismatch repair gene mutation (245 in MLH1, 299 in MSH2, 38 in MSH6, and 19 in PMS2) from 286 families contributing 26,027 person-years, of which 126 (21%) were diagnosed with endometrial cancer Table 2 shows no statistically significant evidence for an association between BMI and endometrial cancer risk for carriers of mutations when all carriers of mismatch repair gene mutation are combined (hazard ratio 0.73 per 5; 95% CI 0.40 -1.34; Pϭ.31) after adjusting for age at menarche, year of birth, hormonal contraceptive use, and cigarette smoking at age 20 years and specific mismatch repair gene mutated. Table 3 presents associations for BMI and endometrial cancer risk separately for carriers of mutations in each mismatch repair gene.
For noncarriers, endometrial cancer risk was estimated to increase by 74% for each increase of 5 kg/m 2 in BMI (hazard ratio 1.74; 95% CI 1.27-2.37; PϽ.001) after adjusting for age at menarche, year of birth, hormonal contraceptive use, and cigarette smoking at age 20 years. The hazard ratio for noncarriers was greater than that for carriers (interaction between mutation carrier status and BMI; Pϭ.04).
There was no evidence for a nonlinear association between (log) BMI (as a continuous variable) and the hazards for endometrial cancer for either carriers or noncarrier (Pϭ.90).
DISCUSSION
The findings of this study suggest that there is a positive association between BMI in early adulthood and risk of endometrial cancer but only for noncarriers of a germline mutation in a mismatch repair gene. We observed no statistical evidence of an association between BMI in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers. Because mutation carriers and noncarriers for this study are from the same families (all noncarriers are relatives of carriers), this study directly compares the association between BMI at HR, hazard ratio; CI, confidence interval. * Adjusted for age at menarche, year of birth, use of hormonal contraceptives, and cigarette smoking at age 20 years, with robust variance correction for familial correlation in risk.
early age (18 -20 years) and endometrial cancer risk for carriers with that for noncarriers. Our study and previous studies based on mismatch repair gene mutation carriers 14 and those having endometrial cancers with microsatellite instability 30, 31 suggest that obesity does not appear to be involved, or at least is less involved, in the development of endometrial cancer for mismatch repair gene mutation carriers than it is for noncarriers. A reasonable supposition consistent with these observations is that endometrial carcinogenesis in mismatch repair gene mutation carriers is not through the estrogenic pathway of the most prevalent form of the disease. Type I endometrial cancers (80% of all endometrial cancers) are mostly low-grade endometrioid carcinomas associated with the following estrogen-predominant conditions: metabolic syndrome (central obesity, noninsulin-dependent diabetes mellitus, dyslipidemia, and hypertension), early menarche, late menopause, infertility, and hyperplasia of the stroma of the ovaries and endometrium. 32, 33 Type II endometrial cancers are predominantly serous and clear cell adenocarcinomas arising from polyps or atrophic endometrium of older women and not thought to be related as strongly to estrogenic stimuli as are type I tumors. [32] [33] [34] [35] Although the predominant histologic subtype in Lynch syndrome-associated endometrial cancers is endometrioid, 36 -39 they are generally high grade and consistently show lymphangioinvasive growth and tumor-infiltrating lymphocytes. [37] [38] [39] These features, together with our finding of no evidence that BMI predicts endometrial cancer risk for mutation carriers, are consistent with the hypothesis that Lynch syndrome-associated endometrial cancers may arise through alternative carcinogenic pathways that are independent of estrogenic stimulation and insulin resistance and therefore may be more like the group of tumors associated with type II endometrial cancer.
Because mismatch repair gene mutation carriers are rare in the general population, 2 our finding of a positive association between BMI in early adulthood and endometrial cancer for noncarriers can be interpreted as an association applicable to the general population. Our finding for noncarriers is consistent with previously published studies [17] [18] that observed a positive association between BMI in early adulthood and subsequent endometrial cancer risk for the general population. In terms of the size of effect, the association we found is similar to previous studies; for example, Schouten et al 17 reported a relative risk per kilogram per square meter of 1.07 (95% CI 1.02-1.12).
The strengths of our study include the use of weighted cohort analysis, which could avoid any selection bias caused by the oversampling of participants from high-risk families 21 ; the use of a robust variance correction, which accounts for dependence between participants from the same family 27, 28 ; and the use of standardized epidemiologic assessment and uniformly high-quality testing for mismatch repair gene mutations across the Colon Cancer Family Registry. 19 A potential limitation of this study is that participants often had to recall weight many years in the past. However, other studies have shown measures of weight taken at age 20 -30 years are well correlated with recalled values at age 50 -70 years with correlation coefficients ranging between 0.73 and 0.95. 40 -42 There is a possibility of response bias in which endometrial cancer affected women recall their weight at age 20 years differently than unaffected women. Finally, because cases with poorer survival were less likely to be included in this analysis (as unable to provide a blood sample for genetic testing and complete a questionnaire), there is a possibility of survival bias if mortality of cases was related to both BMI and mutation status.
In conclusion, our data suggest that BMI in early adulthood might not influence the risk of endometrial cancer risk for carriers of mismatch repair gene mutations. Given the strong association between BMI and endometrial cancer for noncarriers (and the general population), the lack of association for mutation carriers is suggestive of pathways of endometrial carcinogenesis that are independent of obesity.
